CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
C

pulmonary arterial hypertension

Comorbid ConditionsDisease / conditionriskpartially modifiable
11
evidence score
PREVENT status

Not a PREVENT input variable.

Causal support

trial evidence

Score components
lit volume: 3meta-analyses: 0trials: 8.4genetic: 0MR bonus:

References (1)

0 meta-analyses / systematic reviews

Clinical trials (6)

NCTTitleStatusTypeInterventions
NCT05968859Peripheral Limitations in Pulmonary Hypertension and Effects of Muscle Training - The PH Training TrialACTIVE NOT RECRUITINGINTERVENTIONALAerobic Training, Leg Training
NCT04316143An Open-label, Multicentre Study to Evaluate Pharmacokinetics, Safety and Efficacy of Zamicastat as Adjunctive Therapy in Pulmonary Arterial Hypertension (PAH)COMPLETEDINTERVENTIONALOral zamicastat
NCT00303459Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV StudyCOMPLETEDINTERVENTIONALbosentan, placebo
NCT00080457A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment With an Open-Label Bosentan Arm in Patients With Pulmonary Arterial Hypertension (PAH)COMPLETEDINTERVENTIONALsitaxsentan sodium
NCT04278404Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied DrugsRECRUITINGOBSERVATIONALThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
NCT00377949The Natural History and Outcome of Patients With Scleroderma at High Risk for or With Early Pulmonary HypertensionCOMPLETEDOBSERVATIONAL

Genetic associations (0)

None linked.